| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 2, 2024 |
| Accession Number: | 0001753926-24-001987 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ:LGND) and Channel Therapeutics Corporation ("Channel") (NYSE:CHRO), a pioneer i
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical's recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. "We are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators," said Eric Lang, Channel's Chief Medical Officer. "While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company's nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. "We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain," stated Dr. Eric Lang, Chief Medical Officer of Channel. "Addi
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Channel Therapeutics Corp (0001919246) (Issuer)
4 - Channel Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
8-K - Channel Therapeutics Corp (0001919246) (Filer)
10-K - Channel Therapeutics Corp (0001919246) (Filer)
8-K - Channel Therapeutics Corp (0001919246) (Filer)
SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)